ClinicalTrials.gg
Not yet recruitingNCT07503171Updated Mar 31, 2026

Hypoxia and Hemodilution Testing in Healthy Adult Volunteers

An observational study in Hypoxia and Hemodilution, sponsored by Nihon Kohden. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Nihon Kohden · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
7
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hypoxia by Nihon Kohden — 2 open to participants now, 4 under way, none of them phase 3. Hypoxia · Nihon Kohden.

Planned enrollment
9th of 10
7 · median 12
Started
2026
the only one that year
Observational
10 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Hypoxia by Nihon Kohden, this one is the 9th largest by planned enrollment, is the only one that started in 2026, is one of 10 observational ones, and was the 10th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

2 of the 10 studies in Hypoxia by Nihon Kohden are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hypoxia by Nihon Kohden, or all of them as a file.
02

Study summary

This study will collect physiological measurements in healthy adult volunteers under controlled hypoxia and hemodilution conditions.

Read the detailed description

Subjects will undergo stepwise reductions in oxygen saturation and hemoglobin concentration while noninvasive monitoring data are recorded and compared with reference blood measurements.

03

Conditions studied

  • Hypoxia
  • Hemodilution

Browse trials for

Keywords

  • Pulse oximetry
  • Hb
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy adult volunteers. At least 7 subjects will be enrolled. Subjects will be selected with reference to ISO and FDA requirements to ensure appropriate representation across skin tone categories (Monk Skin Tone scale) and sex.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In good general health with no evidence of significant medical problems.
  2. Fluent in both written and spoken English.

4. Has provided written and is willing to comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. above 30.
  2. History of heart, lung, kidney, or liver disease.
  3. Diagnosis of asthma, sleep apnea, or use of CPAP.
  4. Diabetes mellitus.
  5. Clotting disorders.
  6. Hemoglobinopathy or history of anemia (ctHb \<12 g/dL for men, \<11 g/dL for women, COHb >2%).
  7. Any serious systemic illness.
  8. Current smoker.
  9. Injury or abnormality at sensor sites interfering with measurements.
  10. History of fainting or vasovagal response.
  11. Sensitivity to local anesthesia.
  12. Diagnosis of Raynaud's disease.
  13. Unacceptable collateral circulation (Allen's test).
  14. Pregnant, lactating, or attempting to become pregnant.
  15. Unable or unwilling to provide or comply with study procedures.
  16. Any other condition deemed unsuitable by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
7 participants (estimated)
Target follow-up
1 Week
Patient registry
Yes

Groups and cohorts

  • Adult healthy subjects

    Adult healthy subjects capable of undergoing controlled hypoxemia and hemodilution procedures.

    Device: Noninvasive Physiological Monitoring Device

Interventions

  • DeviceNoninvasive Physiological Monitoring Device

    Octopal R Noninvasive Pulse Wave Measuring Device DMO-8000X with TL 811S Finger Probe

06

What researchers measure

Primary outcomes

  1. Collection of Hemoglobin and Oxygen Saturation Measurements

    Collect device readings of oxygen saturation and hemoglobin concentration and reference values obtained from arterial blood samples analyzed using a multi-wavelength laboratory oximeter.

    Time frame: From enrollment to the end of treatment up to 8 hours

07

Study locations

1 site
  • Vital Sign Research Group
    San Francisco, California 94107, United States
08

References and documents

Individual participant data

Plan to share: No — Company confidential

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Feb 2027, 9 months later.

Of 30 industry-sponsored observational studies under Hypoxia, half reached primary completion within 0 months of starting (the median), counting those still running; a quarter within 0 and three quarters within 2.

Counting every sponsor, half of 155 studies reached it within 14 months; a quarter within 3 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Mar 31, 2026
StartEst.
Apr 2, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Jan 31, 2028
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07503171
Lead sponsor
Nihon Kohden
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Apr 2, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Mar 31, 2026

Study contacts

Greg Stratmann, MD, PhD
Contact
stratman@anesthesia.ucsf.edu
(650) 868-5155
Steve Weisner, MS
Contact
steve_weisner@nihonkohden.com
617-318-5904

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion